Current management strategy for high-risk hypertensive patients -focus on lipid-lowering therapy


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article is devoted to the urgent problem of identifying and managing patients with high risk arterial hypertension. The importance of this problem is determined by the fact that the main proportion of cardiovascular complications is accounted for this particular group of patients. In recent years, modern guidelines have emphasized the need to prescribe not only antihypertensive, but also lipid-lowering therapy to these patients. It is noted that lipid-lowering therapy provides an additional reduction in the risk of cardiovascular complications. Unfortunately, high-risk patients are significantly less motivated to treat than patients from the very high-risk group, which causes their lack of adherence to therapy. Nevertheless, at any stage of the cardiovascular continuum, the practitioner must adhere to the golden rule of patient management - to achieve the maximum reduction in the risk of cardiovascular complications.

全文:

受限制的访问

作者简介

D. Nebieridze

National Medical Research Center for Preventive Medicine

Email: dneberidze@gnicpm.ru
MD, Professor, Head of the Department for Prevention of Metabolic Disorders

N. Akhmedzhanov

National Medical Research Center for Preventive Medicine

A. Safaryan

National Medical Research Center for Preventive Medicine

参考

  1. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. от имени участников исследования. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014;10:4-12. Doi: https:// dx.doi.org/10.18565/cardio.2014.10.4-12
  2. ESH/ESC Guidelines for the management of arterial hypertension. J Hypertension. 2013;31(7):1281-1357. doi: 10.1097/01. hjh.0000431740.32696.cc
  3. Диагностика и лечение артериальной гипертензии. Российские рекомендации V пересмотр. Кардиологический вестник. 2015;1(10):3-30
  4. Оганов РГ, Масленникова Г Я., Колтунов И.Е. и др. Необходимые условия для профилактики сердечно-сосудистых и других неинфекционных заболеваний в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2010;9(6):4-9
  5. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339
  6. Sever PS., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58. doi: 10.1016/S0140-6736(03)12948-0.
  7. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22. N. Engl J. Med. 2004;350:1495-504. Doi: 10.1056/ NEJMoa040583.
  8. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., et al. Apolipoprotein E. genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 2001;158(1):183-93. doi: 10.1016/s0021-9150(01)00410-5.
  9. Amarenco P., Bogousslavsky J., Callahan A., et al. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL). N. Engl J. Med. 2006;355:549-59. doi: 10.1056/NEJMoa061894.
  10. Pitt B., Waters D., Brown W.V., et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N. Engl J. Med. 1999;341:70-6. Doi: 10.1056/ NEJM199907083410202
  11. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl J. Med. 2005;352(14):1425-35. Doi: 10.1056/ NEJMoa050461.
  12. Brugts J.J., Yetgin T., Hoeks S.E., et al. Benefitsof statins without established cfrdiovascular disease but with cardiovascular risk factors meta analysis of randomized controlled trials. BMI. 2009;338:b2376. doi: 10.1136/bmj.b2376.
  13. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818. doi: 10.1093/eurheartj/ehr158.
  14. Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., и др. Российские рекомендации V. пересмотра. Российский кардиологический журнал. 2012;5(97):1-32.
  15. Ахмеджанов Н.А., Небиеридзе Д.В., Сафарян А.С. и др. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования арго): часть I. Рациональная фармакотерапия в кардиологии. 2015;11(3):253-60
  16. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialist' Collaboration. BMJ. 1994;308:81-106. Doi: https://doi. org/10.1136/bmj.308.6921.81
  17. de Gaetano G., Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357:89-95. doi: 10.1016/s0140-6736(00)03539-x
  18. Piepoli M.F, Hoes A.W., Agewall S., et al. ESC Scientific Document Group.2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. doi: 10.1093/eurheartj/ehw106

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2019
##common.cookie##